Revlimid
Bristol Myersâ new CEO aims to boost weak new drug launches
Anika Sharma
Bristol Myers Squibb (BMS) is addressing concerns about its underperforming new products, expressing confidence in their future success. The company’s ...
BMS Layoffs Over 100 Employees Lose Jobs After Earnings Miss
SG Tylor
Bristol Myers Squibb, a prominent pharmaceutical company headquartered in New Jersey, has undertaken a significant reorganization of its financial structure ...
Bristol Myers lowers the company’s 2023 revenue forecast for Revlimid by $1 billion
SG Tylor
Bristol Myers Squibb (BMS) had a promising long-term outlook after securing FDA approvals for three drugs with peak sales potential ...
